Advertisement
GOSS vs XBIO
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GOSS is a Hold and XBIO is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
GOSS’s FA Score shows that 0 FA rating(s) are green whileXBIO’s FA Score has 1 green FA rating(s).
- GOSS’s FA Score: 0 green, 5 red.
- XBIO’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
GOSS’s TA Score shows that 6 TA indicator(s) are bullish while XBIO’s TA Score has 0 bullish TA indicator(s).
- GOSS’s TA Score: 6 bullish, 4 bearish.
- XBIO’s TA Score: 0 bullish, 2 bearish.
Price Growth
GOSS (@Biotechnology) experienced а -6.77% price change this week, while XBIO (@Biotechnology) price change was +1.91% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -0.63%. For the same industry, the average monthly price growth was +13.05%, and the average quarterly price growth was +4.06%.
Reported Earning Dates
GOSS is expected to report earnings on Aug 12, 2025.
Industries' Descriptions
@Biotechnology (-0.63% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| GOSS | XBIO | GOSS / XBIO | |
| Capitalization | 282M | 4.65M | 6,070% |
| EBITDA | -35.7M | -3.88M | 921% |
| Gain YTD | 37.077 | -24.489 | -151% |
| P/E Ratio | N/A | N/A | - |
| Revenue | 125M | 2.58M | 4,839% |
| Total Cash | 258M | 5.16M | 4,996% |
| Total Debt | 203M | 153K | 132,680% |
GOSS | XBIO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 59 Fair valued | 18 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 97 | |
PRICE GROWTH RATING 1..100 | 38 | 81 | |
P/E GROWTH RATING 1..100 | 100 | 100 | |
SEASONALITY SCORE 1..100 | 85 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
XBIO's Valuation (18) in the Biotechnology industry is somewhat better than the same rating for GOSS (59) in the Pharmaceuticals Major industry. This means that XBIO’s stock grew somewhat faster than GOSS’s over the last 12 months.
XBIO's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as GOSS (100) in the Pharmaceuticals Major industry. This means that XBIO’s stock grew similarly to GOSS’s over the last 12 months.
XBIO's SMR Rating (97) in the Biotechnology industry is in the same range as GOSS (100) in the Pharmaceuticals Major industry. This means that XBIO’s stock grew similarly to GOSS’s over the last 12 months.
GOSS's Price Growth Rating (38) in the Pharmaceuticals Major industry is somewhat better than the same rating for XBIO (81) in the Biotechnology industry. This means that GOSS’s stock grew somewhat faster than XBIO’s over the last 12 months.
GOSS's P/E Growth Rating (100) in the Pharmaceuticals Major industry is in the same range as XBIO (100) in the Biotechnology industry. This means that GOSS’s stock grew similarly to XBIO’s over the last 12 months.
| GOSS | XBIO | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 80% | N/A |
| Stochastic ODDS (%) | 3 days ago 83% | N/A |
| Momentum ODDS (%) | 3 days ago 78% | N/A |
| MACD ODDS (%) | 3 days ago 87% | N/A |
| TrendWeek ODDS (%) | 3 days ago 88% | about 1 month ago 84% |
| TrendMonth ODDS (%) | 3 days ago 83% | about 1 month ago 83% |
| Advances ODDS (%) | 27 days ago 84% | N/A |
| Declines ODDS (%) | 3 days ago 88% | about 1 month ago 87% |
| BollingerBands ODDS (%) | 3 days ago 90% | N/A |
| Aroon ODDS (%) | 3 days ago 90% | N/A |
Advertisement
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| SCCUX | 10.98 | -0.09 | -0.81% |
| Invesco Income Advantage U.S. Fund C | |||
| POSIX | 9.64 | -0.09 | -0.92% |
| Principal Global Real Estate Sec Instl | |||
| MKVFX | 15.81 | -0.16 | -1.00% |
| MFS International Large Cap Value R3 | |||
| CSPIX | 14.95 | -0.24 | -1.58% |
| Calvert Global Small-Cap Equity I | |||
| REBYX | 23.83 | -0.46 | -1.89% |
| Russell Inv US Small Cap Equity Y | |||
GOSS and
Correlation & Price change
A.I.dvisor indicates that over the last year, GOSS has been loosely correlated with VIR. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if GOSS jumps, then VIR could also see price increases.
| Ticker / NAME | Correlation To GOSS | 1D Price Change % | ||
|---|---|---|---|---|
| GOSS | 100% | -2.36% | ||
| VIR - GOSS | 41% Loosely correlated | N/A | ||
| IONS - GOSS | 36% Loosely correlated | -0.08% | ||
| ARGX - GOSS | 36% Loosely correlated | -1.51% | ||
| ALT - GOSS | 35% Loosely correlated | -3.22% | ||
| RARE - GOSS | 35% Loosely correlated | -4.58% | ||
More | ||||
XBIO and
Correlation & Price change
A.I.dvisor tells us that XBIO and ELEV have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that XBIO and ELEV's prices will move in lockstep.
| Ticker / NAME | Correlation To XBIO | 1D Price Change % | ||
|---|---|---|---|---|
| XBIO | 100% | -7.01% | ||
| ELEV - XBIO | 28% Poorly correlated | +0.39% | ||
| CGEN - XBIO | 24% Poorly correlated | -1.20% | ||
| ABUS - XBIO | 24% Poorly correlated | -1.40% | ||
| GOSS - XBIO | 23% Poorly correlated | -2.36% | ||
| TSHA - XBIO | 23% Poorly correlated | -4.15% | ||
More | ||||